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Diminished ovarian reserve (DOR) is associated with a reduced quantity and quality of the
retrieved oocytes, usually leading to poor reproductive outcomes which remain a great
challenge for assisted reproduction technology (ART). Women with DOR often have to
seek for oocyte donation, precluding genetically related offspring. Germline nuclear
transfer (NT) is a novel technology in ART that involves the transfer of the nuclear
genome from an affected oocyte/zygote of the patient to the cytoplast of an enucleated
donor oocyte/zygote. Therefore, it offers opportunities for the generation of genetically
related embryos. Currently, although NT is clinically applied only in women with serious
mitochondrial DNA disorders, this technology has also been proposed to overcome
certain forms of female infertility, such as advanced maternal age and embryo
developmental arrest. In this review, we are proposing the NT technology as a future
treatment option for DOR patients. Strikingly, the application of different NT strategies will
result in an increase of the total number of available reconstituted embryos for
DOR patients.
Keywords: diminished ovarian reserve, poor ovarian response, oocyte quality, germline nuclear transfer, spindle
transfer, polar body transferINTRODUCTION
Ovarian reserve refers to the number of primordial follicles residing in the ovary and determines the
reproductive lifespan of a woman (1). The number of follicles is predetermined at birth, with female
ovaries containing approximately 1,000,000 immature oocytes (2). After birth, this number
progressively decreases due to apoptosis and cyclic recruitment of follicles in every menstrual
cycle, until menopause, after which the number of follicles will have been reduced to about 1,000 (3).
Reproductive efficiency decreases over the years due to this follicular loss, but also as a result of the
decreasing quality of the remaining oocytes due to reported increased aneuploidy rates, low
fertilization competence, compromised mitochondrial function and higher spontaneous abortion
risk (1, 4, 5). The efficiency of the female reproductive outcome reaches a peak in the mid-20s and
starts declining slowly, dropping dramatically after 37 years of age (4, 6).
Diminished ovarian reserve (DOR) is characterized by a decrease in the quantity of the ovarian
follicular reserve and is mostly attributed to the advanced age of the patient, but also to non-n.org February 2021 | Volume 12 | Article 6353701
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interventions, therapies for cancer treatment (7–13). Increased
levels of Follicle stimulating hormone (FSH >10 mIU/ml), low
Antral follicle counts (AFC <5–7 follicles), and decreased Anti-
Mullerian hormone (AMH) levels (<0.5–1.1 ng/ml) are markers
for DOR diagnosis (14). Patients with DOR have an occurrence
of 31% in ART (15) cycles and are considered as challenging as
they usually display poor ovarian response (POR), leading to a
lower number of retrieved oocytes and subsequently fewer
embryos available for transfer, with resulting poor pregnancy
and life birth rates (LBR) (16). Bologna and POSEIDON
(Patient-Oriented Strategies Encompassing IndividualizeD
Oocyte Number) criteria are being used as means to identify
and treat these patients (17–19).
The incidence of POR patients in the ART setting might vary
between 6 and 35% (20) while it can be over 50% in women over
their forties (21). Several treatment strategies for these patients
are being investigated as means to increase the oocyte yield and
improve the LBR. These approaches include changes in the type
and dose of gonadotropins, stimulation protocols, the use of
adjuvants, double stimulation cycles and the manipulation of
ovarian tissue for primordial follicle activation. The choice of the
appropriate treatment depends on the characteristics of the
patient (22–30). Despite the current attempts to improve the
poor ovarian response to hormonal stimulation (18, 31, 32),
current strategies remain experimental or inconclusive. Child
adoption or oocyte donation remains the only options for some
patients to fulfil a child wish (33, 34).
DOR in aged women has also been associated with
concomitant poor oocyte quality (35–37). Poor oocyte quality
is linked to cytoplasmic insufficiency, as several cytoplasmic
factors, including mitochondria, metabolites, maternal RNAs
and proteins, are important regulators of oocyte and embryo
competence (38). In comparison with the quantitative decrease
in oocyte numbers, oocyte quality is not easy to assess. In the
ART setting, oocyte quality has been linked to morphological
features of the oocytes, embryo arrest, blastulation, implantation,
pregnancy, miscarriage, and euploidy rates. The ultimate marker
is the live birth of a healthy offspring (36). Oocyte quality does
not seem to be affected in young DOR patients, when compared
to age matched groups with a normal ovarian reserve (37, 39, 40).
On the contrary, DOR patients of advanced maternal age have
significantly lower chances for a clinical pregnancy when
compared to younger DOR patients, higher miscarriage rates
and lower high-quality embryos, suggesting poor oocyte
quality (40).
Current approaches for assisting patients with DOR and POR
could be expanded with the novel germline nuclear transfer (NT)
technology. NT offers the possibility to transfer the genetic
material of a patient’s oocyte/zygote with compromised
cytoplasm to the cytoplasm of an enucleated oocyte/zygote of a
healthy donor. This technology enables the generation of
embryos, to which both parents have contributed genetically
(41). NT is currently clinically applied in a strict subset of
patients suffering from mitochondrial DNA (mtDNA)
disorders, aiming to overcome maternal mutant mtDNAFrontiers in Endocrinology | www.frontiersin.org 2transmission to the next generation. Besides, increasing interest
has been shown in the application of NT to overcome certain
types of female-related infertility (42), which is supported by
some promising studies in animal models (42, 43), but still, peer-
reviewed reports in human patients remain scarce. The rationale
of this treatment is that by transferring the nuclear DNA from an
oocyte with inferior quality cytoplasm to an oocyte with more
competent cytoplasm, like the ones of young, fertile women,
could potentially improve embryo development. In this review,
we propose the NT technology as a possible novel treatment
method for DOR patients in order to increase the number or/and
quality of the retrieved embryos.DIFFERENT NUCLEAR TRANSFER
TECHNIQUES
For normal fertilization to occur, an oocyte needs to be at the
correct maturation state, both cytoplasmic as nuclear. Before
ovulation, oocytes are arrested in meiotic prophase I. They are
diploid, having both paternal and maternal genomes, and DNA
resides in the nucleus (germinal vesicle (GV)). Following meiotic
maturation, oocytes arrest in the metaphase of meiosis II (MII
oocyte). Chromosomes are aligned on the spindle, while the
oocyte extrudes the first Polar body (PB1) containing the
homologous chromosomes. At this stage, the oocyte can be
fertilized by the sperm. Following fertilization, the oocyte
completes Meiosis II, extruding first a second Polar body (PB2)
and forming the maternal and paternal pronuclei, generating the
zygote. The PB2 contains the haploid sister chromatids of the
maternal pronucleus (44). The NT technology can be performed
at different stages of oocyte maturation: Germinal vesicle transfer
(GVT), Spindle transfer (ST) or Polar body 1 transfer (PB1T) or
at the zygote stage: Pronuclear transfer (PNT) or Polar body 2
transfer (PB2T).
During GVT, the nucleus of a GV oocyte is being transferred
in an enucleated GV donor oocyte (Figure 1). The reconstructed
oocyte needs to undergo in vitro maturation before it can be
fertilized by the sperm (45). In ST, the spindle-chromosome
complex (containing the DNA) of an MII oocyte is transferred to
an enucleated (DNA free) MII donor oocyte which is
subsequently fertilized by the sperm of the patient’s partner
(46) (Figure 1). At the MII stage, also PB1T may occur. PB1T
includes the transfer of the first polar body into an enucleated
MII oocyte, followed by fertilization (Figure 1). In PNT, the
pronuclei from the patient’s zygote can be transferred in the
cytoplasm of an enucleated donor zygote that will serve as a
recipient (46) (Figure 1). At this stage, also PB2T may occur,
which involves the transfer of PB2 in an enucleated donor oocyte
containing only the male pronucleus from the partner’s sperm.
The paternal pronucleus can be obtained in two ways: a.
Fertilization of the donor oocyte with sperm and subsequent
removal of the maternal pronucleus (46, 47) or b. Enucleation of
a mature oocyte and subsequent fertilization by the partner’s
sperm. In this case, only one pronucleus is formed. Polar body 2
can be transferred in the zygote with the male pronucleus andFebruary 2021 | Volume 12 | Article 635370
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appropriate in human, as it is hard to distinguish between
male and female pronucleus (Figure 1).
NT techniques have been tested in several species, including
non-human primates. Mice have been used as models in the vast
majority of published papers to evaluate the efficacy of this
technology due to the ir fas t reproduct ion , eas ier
manipulations, and abundancy of gamete cells. Another benefit
of making use of these species is some conserved similarities with
humans regarding the events of gametogenesis and early
embryonic development (49). Following fertilization, the
formation of the two pronuclei in the mammalian species
signals the zygote formation. Zygote formation is followed by
consecutive divisions of the newly formed embryo. Embryonic
genome activation (EGA) is an important event that occurs after
the first cell divisions, and it differs according to the species: in
mouse: two-cell stage and in human between four and eight cells
(50). Before EGA, the maternal proteins and mRNAS already
present in the oocyte direct almost exclusively the first events of
fertilization and embryonic development. Following EGA,
embryonic cells compact and polarize to form two distinct
cellular populations at the blastocyst stage. In mammals,
embryos will implant at this stage, following the release of the
blastocyst from the zona pellucida. Besides the similarities atFrontiers in Endocrinology | www.frontiersin.org 3these early embryonic stages, mice do display important
differences when compared to larger mammals and humans.
Embryonic developmental events occur faster in the mouse
species. The events of EGA, cell division, compaction,
blastulation, and implantation occur much faster in mice
compared to human (49). Furthermore, mouse embryos have a
prominent good embryonic development (reaching
approximately 80% blastocyst rate) when cultured in vitro,
when compared with larger mammalian species, including
humans. In addition, meiotic errors in mouse oocytes are less
evident than in human, with an estimated incidence of 1 and 5–
20% respectively. Moreover, human embryos appear to have
high numbers of mosaicism and aneuploidy rates than mouse
embryos (49). Although mammalian species have served as good
models to study the efficacy and safety of NT, species-specific
differences usually demand a fine-tuning of the technology in the
human species but also careful interpretation of the results.
For the abovementioned reasons, optimization of the
technique in human oocytes was necessary before
consideration of any future clinical application. These studies
have focused on the efficiency of the NT technology using human
oocytes regarding reconstruction and blastocyst rates and the
amount of cytoplasmic carry-over from the oocyte that serves as
a nuclear donor. A previous study by Craven et al. (51),FIGURE 1 | Different nuclear transfer (NT) techniques can occur at the oocyte or the zygote stage. Reconstruction at the oocyte stage: Germinal vesicle transfer
(GVT): the nucleus is transferred in an enucleated GV oocyte. Following in vitro maturation, the reconstructed oocyte can be fertilized by the patient’s partner sperm.
Spindle transfer (ST): The spindle from a mature oocyte (MII) is transferred to the enucleated MII donor oocyte. Polar body 1 transfer (PB1T): The first polar body
from an MII oocyte is transferred to an enucleated MII oocyte of a donor. Reconstruction at the zygote stage: Pronuclear transfer (PNT): the pronuclei from a fertilized
oocyte are transferred to the enucleated donor zygote. Polar body 2 transfer (PB2T): The second polar body of a fertilized oocyte is transferred to a zygote
containing the male pronucleus of the patient’s partner. The paternal pronucleus can occur in two ways: (a) by fertilization of a donor’s oocyte. Following fertilization,
the male and female pronuclei form. The female pronucleus of the donor can be removed and replaced by the second polar body of the patient’s MII oocyte. (b) The
donor’s MII oocyte is enucleated and injected with the partner’s sperm. Following the formation of the male pronucleus, the second polar body from a patient’s
zygote can be transferred.February 2021 | Volume 12 | Article 635370
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and 3PN). Reconstruction was successful, with less than 2%
mitochondrial DNA carry-over from the nuclear donor.
Nevertheless, a very low blastocyst formation rate was
observed (8.3%) in comparison to unmanipulated controls
(51). The PNT procedure was further optimized using
normally fertilized zygotes and by refining the timing of the
procedure. Early PNT, performed at 8 h post-ICSI was shown to
be beneficial upon late PNT at 16 h post-ICSI. This adapted
methodology was shown to significantly increase the blastocyst
rates of the reconstructed zygotes, to a level of the non-
manipulated controls (52). The first study to perform ST in
human MII oocytes was published by Tachibana et al. (53),
which confirmed the feasibility of the technique in human
oocytes. Blastocyst rate in reconstructed oocytes following
normal fertilization showed similar results with control
fertilized oocytes (62 vs 76%). Human embryonic stem cells
(hESCs) were also derived from the reconstructed embryos,
carrying low levels of mtDNA from the nuclear donor (53).
While ST and PNT have been mostly studied in the human, only
one study has been reported making use of the PB1T strategy.
Reconstructed PB1T oocytes were capable of normal
fertilization, and PB1T zygotes developed to the blastocyst
stage, but yet in a lower rate (42%) compared to the control
group (75%) (54). PB2T studies in the human have been scarcely
described, possibly due to the difficulty of distinguishing between
male and female PNs (47). Mouse models using this technology
have proven very promising but nevertheless, in the mouse it is
easy to distinguish between female and male pronucleus, due to
their evident size difference (47). The novel PB2T described by
Tang et al. (48), optimized the use of PB2T in human oocytes and
proved its efficacy. GVT remains challenging, as oocyte in vitro
maturation is not yet optimized. In a mouse model, GVT oocytes
were able to undergo maturation and cleave, but all embryos
arrested before the blastocyst stage (55). In human, more studies
are needed to improve the efficiency of the technique before it
could be considered for clinical application, as still, in vitro
maturated oocytes are inferior compared to their in vivo
counterparts (56).APPLICATIONS OF GERMLINE NUCLEAR
TRANSFER
Nuclear Transfer for Mitochondrial
Diseases
NT techniques have initially been proposed to prevent the
transmission of mtDNA diseases from the mother to the
offspring. Mitochondrial disorders are reported to affect one in
5,000 individuals and are attributed to mutations or deletions in
the mitochondrial DNA (mtDNA). Mitochondria are semi-
autonomous organelles, important for the energy production
and metabolism of the cell. They hold their own genome
(mitochondrial DNA, mtDNA) in a variety of copies, coding
for 37 genes. Other genes important for mitochondrial functions
are encoded by the nuclear genome of the cell. Thus,Frontiers in Endocrinology | www.frontiersin.org 4mitochondrial function is under dual genetic control of both
the mitochondrial and nuclear genome (57). Mitochondria are
exclusively inherited only from the mother (58, 59) with a few
rare exceptions being reported recently of possible paternal
inheritance (60). Oocyte mtDNA mutations either reside in a
homoplasmic state, with all of the copies carrying the mutation,
or in a heteroplasmic state, presenting a mixture of mtDNA
mutated and wild-type copies. The degree at which heteroplasmy
occurs can differ between cells and tissues of one individual but
can also shift in between generations. This can be attributed to
the processes occurring during the formation of the female
germline. At the stage of primordial germ cell formation, the
number of mtDNA copies decreases significantly, which is a
phenomenon designated as the mitochondrial genetic bottleneck
(61). For women carrying heteroplasmic mtDNA mutations, this
process can trigger a shift in heteroplasmy levels in the produced
oocytes and makes it therefore difficult to predict the mutational
load (number of affected mtDNA copies) in the corresponding
generated embryo. Until now, there are no treatments available
to el iminate mitochondria l diseases , only ways of
prevention (62).
Pre-implantation genetic testing (PGT) has been used to
determine the level of pathogenetic mtDNA copies in in vitro
generated embryos in order to select mutation-free or mutation-
low embryos which will not be affected by a mitochondrial
disease (63). The mutational load should be less than 18% for
an embryo to be considered safe for transfer, as calculated by a
meta-analysis study by Hellebrekers et al., regardless the type of
mtDNAmutation (64). Nevertheless, PGTmight have diagnostic
limitations, as embryonic mitochondria may shift their
heteroplasmy levels during cell division, and mitochondrial
mutations may be favored in response to environmental
influences over wild type copies. In addition, patients carrying
homoplasmic DNA mutations cannot be helped by PGT (65).
The NT technology can be beneficial for both patients
carrying homoplasmic mutations, as well as for patients
carrying heteroplasmic mutations for which no embryos with
mtDNA mutational levels below 18% can be identified by PGT.
By transferring the nuclear genetic material of the patient’s
diseased oocyte/zygote to an enucleated, donated oocyte/
zygote, containing healthy mtDNA copies, the reconstructed
embryo is genetically related to both parents, with mtDNA
being associated to the oocyte or zygote donor (66). During
NT, it is inevitable that a minimal amount of cytoplasm is being
transferred along, so a certain amount of the patient’s mtDNA
copies will be present in the reconstructed NT embryos as well,
which is known as the carry-over (67).
NT is a quite controversial topic in the field of ART, as it
remains a new technology, and little is known about the effect on
the health of the offspring. Studies in animal models
demonstrated the feasibility of this technique and the potential
to prevent mitochondrial diseases (47, 55, 68). A number of
preclinical studies in human have also reported the carry-over of
the patient’s oocyte to the donor’s cytoplasm and also verified the
efficacy of PNT, ST, and PBT (52–54, 69). The first live birth in
human was published in 2017, where the NT technology wasFebruary 2021 | Volume 12 | Article 635370
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mitochondrial disease, to the offspring (70). The patient had a
long history of undiagnosed pregnancy losses and offspring
death due to the disease. Following ST of the patient’s oocytes
into enucleated oocytes of a donor and subsequent fertilization
with the partner’s sperm, a healthy baby was born. The offspring
was carrying low levels of mutant maternal mtDNA (2.36–9.23%
in the tested tissues), indicating both the efficacy of the technique
to prevent mitochondrial diseases, as well as the occurrence of
carry-over (70). As the US is currently restricting the use of NT
for infertility treatments, the patient was treated in Mexico. To
date, one center in the UK is already applying NT technology to
overcome the transmission of mtDNA diseases, and is
extensively following up the health of the babies born (71, 72).
Nuclear Transfer for Female-Related
Infertility Treatments
Nuclear Transfer to Treat Fertilization Failure and
Embryo Developmental Arrest
Infertility affects 8% to 12% of couples worldwide, and both
female and male factors may contribute to it (73). The evolution
of ART has helped many couples worldwide to deliver a healthy
baby, but the treatment of some couples remains a challenge.
Two not well characterized cases of infertility are failed
fertilization (FF) following ICSI and embryo developmental
arrest (EDA) (74, 75).
Although ICSI has offered promising results in the field of
ART with fertilization rates of 70% to 80%, FF still occurs in 1%
to 5% of ICSI cycles (76). Oocyte activation deficiencies are the
main reason for FF and can be attributed to both oocyte- and
sperm-related factors. Following sperm injection, the sperm
initiates a series of events in order to activate the arrested
metaphase II oocyte. Following fertilization, a rise in Ca+2
peaks occurs within the oocyte, which is important for its
activation and subsequent embryo development (77). In
patients with FF after ICSI, these peaks can be abnormal or
absent. Currently, assisted oocyte activation (AOA) has been
proven beneficial for most of these patients. AOA involves the
production of Ca+2 oscillations artificially by different methods,
such as the use of calcium ionophores (78, 79). Albeit promising
for FF related to sperm-related deficiencies (80), when it comes
to oocyte-related factors, AOA is not always efficient in these
patients (81), who have to seek for oocyte donation (82). Oocyte
factors are attributed to compromised cytoplasmic quality, such
as reduced mitochondrial numbers or abnormal proteins
involved in fertilization (83, 84). Up to now, only mutations in
four female genes (PATL2, WEE2, TLE6 and TUBB8) have been
linked to FF (85), while AOA was not beneficial for women with
WEE2 mutations (86, 87). Nevertheless, injection of the WEE2
cRNA led to successful activation of the affected oocytes,
allowing the formation of blastocysts (85), suggesting that
cytoplasmic incompetence can be overcome by enriching the
oocyte with the normal cRNA. The use of NT could possibly help
these patients when a sperm-related factor is excluded. The
compromised cytoplasm of the affected oocytes could be
replaced by the cytoplasm of a donor oocyte by transferringFrontiers in Endocrinology | www.frontiersin.org 5the genetic material of the patient to the donor oocyte. There are
currently no publications suggesting the use of NT to rescue FF
in patients with oocyte activation deficiency factors, as oocyte
factors are not yet well characterized. Oocyte factors are complex
to study, not only because oocytes are scarce for research
purposes, but also because a large number of maternal factors
are involved in the oocyte activation process (88). Specifically,
errors can occur in the oocyte Ca2+ realizing machinery, in the
pathways activated downstream the Ca2+, in the channels and
pumps involved in Ca2+ homeostasis, but also due to a poor
overall oocyte quality or nuclear defects (88).
Another not well understood condition is embryo
developmental arrest. EDA is characterized by the primary
arrest of embryos in the early cleavage stages (75).
Approximately, 10 to 15% of IVF embryos arrest permanently,
and some patients present recurrent complete embryo
developmental arrest (89). Before embryonic genome
activation (between four and eight cells in human), embryonic
development is almost exclusively regulated by maternal RNAs
and proteins stored in the cytoplasm (50). The genes encoding
for these essential maternal factors are the so-called maternal
effect genes (MEGs). Over 60 oocyte-specific MEGs have been
found to be critical for mammalian development (90). However,
research in human is still limited, and only few MEGs, some of
which form the subcortical maternal complex (SCMC) have been
identified. The SCMC is a multiprotein complex, composed of at
least six proteins, that participates in the zygote genome
activation, but its exact functions are still under debate (91).
Recently, mutations in the genes involved in the formation of the
SCMC, such as TLE6, PADI6, NRLP2, NRLP5, NRLP7, and
KHDC3L have been detected in patients suffering from EDA
(92–96). For patients facing EDA, the only current solution
remains oocyte donation. As a treatment to embryo
developmental arrest, NT could be proposed.
Two recent publications (42, 43) investigated the use of NT
technology to overcome embryo developmental arrest in a
mouse model. Nuclear transfer (both ST and PNT) between
oocytes from NZB/OlaHsd mice that display a two-cell blockage
and control B6D2 mice, rescued the embryonic development,
resulting in high blastocyst rates (42). The use of ST by of Costas-
Borges et al (43), using the same mouse model, demonstrated
similar results but also low carry-over rates of maternal
mitochondrial DNA and low heteroplasmy levels in the
offspring for several generations, as well as normal fertility of
the pups from the reconstructed embryos (43).
A recent study by Bai et al. (97), reported on the use of
different NT techniques to overcome embryo developmental
arrest in a Zar1−/− mouse model. Zar1 is an important
regulator of maternal genome degradation and embryonic
genome activation. Zar1−/− mice displayed embryo
developmental arrest. In order to rescue the development of
these embryos, NT technology was applied, including ST or
PB1T between Zar1−/− and wild type mouse oocytes, or early
and late PNT between Zar1−/− and wild type zygotes. ST, early
PNT, and PB1T significantly increased the blastocyst stage of the
reconstructed oocytes/zygotes and also led to live offspring inFebruary 2021 | Volume 12 | Article 635370
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PB1T group, comparable to the control group. Furthermore,
the resulted offspring were healthy and fertile. Nevertheless, the
delivery rate for late PNT was only 2.82% in the reconstructed
zygotes (97).
In human, the first NT report to overcome embryonic arrest
was reported in 2016 by Zhang et al. (98). PNT was applied for a
patient with recurrent embryonic arrest at two-cell stage,
following fertilization. The transfer of the pronuclei into the
zygote of a donor, resulted in five four-cell stage embryos and a
triplet pregnancy, although no live birth was achieved (98).
FF and EDA remain the challenges for ART, and cytoplasmic
oocyte quality is of great importance for appropriate embryonic
development. Current data are encouraging but not sufficient to
support the use of NT for infertility treatment. Yet, two clinics in
Greece and Ukraine are claiming live births by making use of the
NT technology for female-related infertility, but peer-reviewed
publications are currently lacking.
Nuclear Transfer for Advanced Maternal Age
In IVF clinics, women over the age of 37 years remain a
challenging population for ART. Advanced maternal age is
accompanied by ovarian aging, which is characterized by a
decline in both quantity and quality of oocytes (99). Poor
oocyte quality in aged women is associated with cytoplasmic
deficiencies and impaired mitochondrial function, which has a
negative impact on the ATP supply to support oocyte maturation
and embryo development (100, 101). The mtDNA copies in a cell
are directly correlated with its metabolic needs. In mature human
oocytes, for instance, the number of mtDNA copies is
approximately 100,000–600,000 (62). Importantly, a threshold
of mtDNA copies has been suggested for successful fertilization
and subsequent embryonic development (101). Women of
advanced maternal age generate more aneuploid embryos
compared with younger women (102). An oocyte has high
energy demands for the formation of the meiotic spindle and
the correct alignment of the chromosomes, but also to complete
maturation, fertilization, and support the first cleavage stages of
embryonic development (101). Mitochondria are maternally
inherited, and no mitochondrial replication occurs before the
blastocyst stage. Thus, the number of mtDNA copies in the
oocyte is important for the first steps of embryonic development
(100). The mtDNA copy number in the oocytes of older women
is significantly decreased compared to those of younger women
(103). This number is also reduced in the early cleaved embryos,
while it is higher in blastocysts of older women. Nevertheless,
this high number of mtDNA copies in blastocysts of older
women has been associated with increased aneuploidy and
failed implantation (104).
Despite the mitochondria, other cytoplasmic factors are also
important for fertilization and proper embryonic development,
such as organelles, metabolites, maternal RNAs and proteins, as
descripted in the previous section (38, 105). A recent study by
Bertoldo et al. (106), reported that poor oocyte quality from
reproductive aged mice was associated with reduced levels of the
metabolic cofactor nicotinamide adenine dinucleotide (NAD+).Frontiers in Endocrinology | www.frontiersin.org 6Supplementation of the NAD+ precursor Nicotinamide
mononucleotide restored oocyte quality and enhanced
blastocyst quality and live birth rates in the aged females (106).
Several methodologies have been explored to overcome the
poor cytoplasmic quality of women with advanced maternal age.
Cytoplasm transfer (CT), which involves injection with a limited
portion of cytoplasm from a competent (donor oocyte) to an
incompetent oocyte (107) and Autologous Germline
Mitochondrial Energy Transfer (AUGMENT) have been
investigated (108). The safety and benefit of CT remain
unclear owing to certain abnormalities observed in the
resultant children (109) although it is not certain that these
abnormalities were caused by CT. Clinical applications of this
technology were put into practice before extended animal
studies, although a recent paper from Tang et al. demonstrated
that CT was not beneficial to overcome cytoplasmic inferiority of
the oocytes from old mice, in contrast to NT (42). Alternatively,
the method of AUGMENT has been investigated. AUGMENT
involves the supplementation of the incompetent oocyte with
autologous mitochondria, isolated from oogonial stem cells
harvested from an ovarian biopsy of the patient (108).
Nevertheless, it is difficult to confirm the efficacy of the
technique due to the small number of patients treated and also
due to the difficulty of isolating oogonial stem cells and the
controversy around their existence in the human adult ovary
(110–113). Furthermore, a recent study reported no benefit in
embryo quality in women with multiple IVF failures using the
AUGMENT technology (111).
NT has been proposed for the indication of advanced
maternal age. In 2009 Mitsui et al. (114), demonstrated the
effectiveness of ST to rescue poor development in embryos
originating from aged mice. Oocytes from young mice were
used as recipients and high blastocyst rates were achieved (114).
Tang et al. (42) achieved also promising results making use of ST
and PNT. Furthermore, spindle assembly and mitochondrial
potential were assessed in oocytes of mice of advanced age. A
significantly higher number of abnormal spindles and misaligned
chromosomes were noticed in the oocytes of aged and very aged
mice compared with oocytes from young mice (42).
Fur thermore , mi tochondr ia l membrane potent ia l ,
representative of mitochondrial function, was severely
compromised in the aged and very aged mouse group.
Mitochondrial membrane potential values were increased in
reconstructed oocytes with spindles from very aged mice
transferred in the cytoplasm of young mice (42). Fertilization
and blastocysts levels following sperm injections were
significantly lower in the aged and very aged mouse group
compared to the one of young mice. PNT significantly
increased the fertilization and blastocyst rate of the
reconstructed oocytes in both aged and very aged groups, after
transfer of the pronuclei into enucleated zygotes from young
oocytes. ST also increased fertilization and blastocyst formation
for the reconstructed oocytes of the aged group but did not
improve the results in the very aged mouse oocytes. Importantly,
euploidy rate was very high in embryos originating from the
reconstructed NT oocytes/zygotes. Opposite results wereFebruary 2021 | Volume 12 | Article 635370
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young mice in the cytoplasm of very aged mice (42). These
results could indicate that ST and PNT might be able to avoid
embryo aneuploidies created during embryo development,
caused by the poor cytoplasmic quality of oocytes from mice
of advanced maternal age. Nevertheless, the number of
blastocysts analyzed in this paper was limited, and the results
should be translated cautiously.
Use of Nuclear Transfer Technology for DOR/POR
Patients
DOR patients are associated with poor reproductive outcomes,
even when ART techniques are used (14). DOR patients usually
exhibit POR due to compromised ovarian reserve (115). Poor
oocyte numbers following stimulation regardless of the age of the
patient or embryo quality have been associated with poor clinical
results in this patient group (16). POR patients appear to be in a
higher risk for foetal aneuploidies compared to normal response
and higher chances for pregnancy loss, Down syndrome and
other embryonic aneuploidies have been associated with patients
with DOR (116–118).
In aged women with POR, poor pregnancy rates have been
reported, as a normal sequence of ovarian ageing. As previously
described, advanced maternal age is characterized by poor oocyte
cytoplasmwhich highly compromises embryonic development and
pregnancy rates (119). Despite the normal fertility decline
associated with age, it is unclear whether this patient group is
associated with higher embryonic aneuploidies compared with age
matched control women. POR patients have similar fertilization,
implantation, aneuploidy, and miscarriage rates compared to aged
womenwith normal response to gonadotropins (16). Nevertheless,
the number of embryos available significantly decreases in POR
patients, affecting the chances for embryo transfer (16).
Poor oocyte and embryo quality do not seem to be the case for
young women with POR (37, 39, 40). Young patients with POR
seem to have similar fertilization rates and good embryo quality
compared to age matched control women. Nevertheless, again,
the number of oocytes retrieved following stimulation affects the
number of available embryos for embryo transfer, resulting in
decreased implantation and LBR. When a blastocyst is acquired,
LBR is comparable to the women with normal ovarian reserve
(39). One of the most important factors in the outcome of ART is
the number of recruited oocytes following ovarian stimulation
(120). A good yield of oocytes renders higher chances for a
sufficient number of euploid embryos (121).
Since cytoplasmic quality and oocyte numbers are important
factors for the outcome in the ART setting, NT could assist these
patients. For the patients with advanced maternal age, DNA
from the patient’s oocytes could be transferred to the cytoplasm
of a healthy young donor. In addition, the low number of oocyte
yields from DOR/POR patients could be overcome by the use of
NT. Here, we are proposing the use of three different NT
techniques that would yield four embryos instead of one,
starting from one patient oocyte (Figure 2).
The first step involves the transfer of the 1st polar body
(PB1T) into an enucleated mature oocyte of a donor.Frontiers in Endocrinology | www.frontiersin.org 7Following fertilization with the sperm of the patient’s partner,
second polar body extrusion occurs with the formation of
pronuclei, belonging to the patient’s genomic DNA and the
one of her partner’s. The remaining spindle in the patient’s
oocyte can be transferred to a second enucleated donor oocyte
and results in a zygote and second polar body extrusion following
fertilization. Two more donor oocytes can be used for the
reconstruction of embryos using the two second polar bodies
after ST and PB1T. Donor oocytes are enucleated and fertilized
with sperm from the partner of the patient. A single male
pronucleus is formed. The second polar bodies from the
reconstructed oocytes can be transferred to the zygote and
results in two more embryos. The technique of this novel
PB2T in human has been successfully optimized recently by
Tang et al. in a research setting (48).
According to the above scheme, making use of only one
patient oocyte, four embryos could be reconstructed with the
help of NT technology. This would allow more available embryos
to be chosen for embryo transfer in this patient group.CHALLENGES IN NUCLEAR TRANSFER
TECHNOLOGY
Despite the promising results of the NT technology in some
animal and human models, results remain scarce on the value of
this technique in clinical practice when mitochondrial diseases
are not involved. Furthermore, a number of concerns have been
raised over the years about the safety of the technique for
the offspring.
Since mitochondrial function is under dual control of both
nuclear and mtDNA, concerns are raised towards the possible
incompatibility of the nuclear DNA (patient) and mtDNA
(donor), which may occur from different mtDNA haplogroups.
Diversity in the mtDNA sequence has been identified between
individuals, with different haplotypes in mtDNA copies.
Individuals fall in different haplogroups, depending on the
characteristics of the mtDNA variants. These haplogroups were
established during human evolution, and they are characteristic
of some geographical regions (66). Nuclear–mitochondrial
incompatibility has been previously reported in an animal
study, reporting high embryonic lethality and stillborn rates in
mice, when applying nuclear transfer between two mouse breeds
(122). Nevertheless, health reports in other studies suggest that
nuclear–mitochondrial incompatibility is not an issue (68, 70).
Furthermore, current evidence also suggests that nuclear transfer
does not affect the mitochondrial function in humans. This was
shown in Embryonic stem cells (ESCs) from reconstructed
blastocysts using NT. ESCs had similar mitochondrial
respiratory chain enzyme activity and oxygen consumption
rates regardless the combination of nuclear–mitochondrial
DNA (53, 123).
Another reason for caution when applying NT is the
occurrence of cytoplasmic carry-over of mutant mtDNA
molecules from the patient’s to the donor oocyte. Even though
reported levels of mtDNA carry-over in reconstructed NTFebruary 2021 | Volume 12 | Article 635370
Christodoulaki et al. Nuclear Transfer for DOR Patientsembryos were always lower than the 18% threshold level for
disease expression (51, 52), the occurrence of heteroplasmy drift
could cause a shift in heteroplasmy levels during development. A
recent study demonstrated a competition between different
mtDNA haplotypes. The heteroplasmic mouse model
containing the C57BL/6JOlaHsd nuclear genome and either
NZB/OlaHsd or C57BL/6JOlaHsd mtDNA showed that one of
the mtDNA haplotypes was becoming predominant, termed as
“haplotype selection”, during oogenesis and early embryo
development, which was dependent on the specific interaction
between the nuclear and mitochondria encoded genes (61).
Despite the low heteroplasmy levels in reconstructed human
embryos, progressive increase in the mtDNA heteroplasmy levels
of several hESC lines derived from reconstructed NT blastocysts
has been reported (52, 123). Whether this is due to the artificial
nature of hESCs or a biological phenomenon has to be further
explored. Since the effect of heteroplasmy on the reconstructed
embryo has not been elucidated yet, the minimal carry-overFrontiers in Endocrinology | www.frontiersin.org 8should be guaranteed. The most studied nuclear transfer
technologies are ST and PNT. Several studies have reported
different levels of carry-over to the reconstructed embryos by the
application of the two techniques; nevertheless it seems that these
two techniques allow a very small amount of mtDNA to be
transferred from the nuclear donor. The minimum carry over
seems to occur with the use of PBT, as polar bodies have a very
small cytoplasmic content (47, 62).
Another limitation for the use of NT technology is that it
would increase the financial cost for the patients. This should be
avoided until the benefits and the safety of the technique are
more concrete for patients with female subfertility. Nevertheless,
these techniques are not so labor intensive, as especially the
model we are proposing can be done during the daily IVF
routine, and PB2T can occur early the next morning. Yet, a
microscope for spindle visualization is required and due to the
sensitivity of the material, users should be well-trained. It is
worthy to note that NT cannot correct all aspects of infertility. IfA
B
C
FIGURE 2 | (A) Polar body 1 transfer (PB1T): The first polar body of a mature oocyte is transferred to a donor mature oocyte from which the spindle has been
removed. Following reconstruction, the oocyte is fertilized, extruding the second polar body. (B) Spindle transfer (ST): The spindle of the patient’s oocyte can be
transferred into an enucleated donor metaphase II (MII) oocyte. The reconstructed oocyte can be fertilized with the patient’s sperm and extrude the second polar
body. (C) Polar body 2 transfer (PB2T): An oocyte of the donor is enucleated and fertilized with the sperm of the patient’s partner. A single pronucleus is being
formed, containing only the genetic material of the partner. Polar body 2 resulting from PB1T or ST can be transferred to the zygote, including now the genetic
material of the patient and the correct genetic load.February 2021 | Volume 12 | Article 635370
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the mother, something that is highly prevalent in aged women
(124), then the NT will not be of benefit (42). In this regard, PGT
to assess aneuploidy should be offered in all cases when NT
embryos are being created as the NT technique is still very novel.
Before any further application of this technology, the ethical
aspects should be considered thoroughly.
The ethical concerns primarily refer to the genetic
modification of the germline. Some argue that NT could cause
genetic modifications that could be transmitted to the next
generation. Nevertheless, unlike other technologies, NT does
not target the DNA of the genome nor of the mitochondria
(125). Although strict regulations and federal organizations have
been established in some countries that control the creation of
embryos for research purposes, prohibiting any use for eugenic
intent, the use of human embryos remains a debatable issue
(126). Furthermore, a number of people argue that women
donating oocytes for research could be exploited, and the
donated oocytes could be seen as a commodity to experiment
the different research techniques (127). The genetic contribution
of the donors has also been criticized. Nevertheless, in the case of
mitochondrial donation, nuclear DNA from the donor is not
contributing to the offspring, in contrast to other cases of oocyte
donation, only the mitochondrial DNA. Finally, one of the most
important ethical concerns for the use of NT is the safety of this
technique to the offspring (127). Although available studies are
promising, the number of applications in human is limited, and
therefore, the technique should be considered as highly
experimental, and thorough follow-up of the children born
after this technology should occur.CONCLUSIONS
DOR patients remain a challenge for current ART practice. Poor
response to gonadotropins and poor oocyte quality lead to the
recruitment of a lower number of good quality oocytes for
fertilization. NT is a new technology being used to overcome
the transmission of severe mitochondrial diseases from mother
to offspring (128). Lately, this technology has been proposed for
certain types of female-related subfertility (98), but scientificFrontiers in Endocrinology | www.frontiersin.org 9reports remain scarce. Making use of the proposed NT scheme
described above, we believe that a higher number of embryos can
be reconstituted for DOR patients when making use of these
various NT strategies. This approach is expected to also
overcome cytoplasmic defects in oocytes of women of
advanced age. Before any application of NT for DOR patients,
more studies should be carried out in animal models before
assessing the safety of the technique on patients suffering from
subfertility and PGT should remain the tool to ensure the safety
of the reconstructed embryos.AUTHOR CONTRIBUTIONS
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